HBOT Conversations:
Dr. Paul Harch & The Science Behind The Practice
Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on The Science Behind the Practice is the fourth in a nine episode series that will be released weekly with Dr. Harch.
Watch the Podcast
di Girolamo asks Dr. Harch to explain his background, and the road he had to take to get to where he is today.
In Episode 4, Dr. Harch tells a miraculous story of how his medical journey with Hyperbaric Oxygen Therapy fell into his lap during his surgical residency. It was during this internship when Dr, Harch was in a horrendous vehicle accident and nearly killed. This led to more than one medical leave of absence. While out on his second leave of absence after yet another surgery, his perspective changed; and he started to wonder what he wanted to do with his life.
After not finding fulfilment in an emergency medicine practice, Dr. Harch decided that he needed to follow his true passion and interest if he was going to have any chance of feeling accomplished, and changing lives.
Dr. Harch had a high level of interest in Navy divers and the extreme cases of brain decompression sickness. He started asking questions about how they were being treated for decompression sickness and why they were not getting better. Dr, Harch refers to the unbelievable cases that landed in his lap as his “Manna from Heaven”. Other doctors tossed these cases to the side, but Dr. Harch decided to try something different with these patients – he treated using lower doses of hyperbaric oxygen therapy. It totally reversed what was going on with these patients!
Even though his results were clinically astonishing, the Medical Societies were surprisingly not impressed or welcoming; forcing Dr. Harch to create more research documentation and do more clinical work to prove his success with hyperbaric oxygen therapy to treat chronic brain issues. During his journey to prove the results, he was implemental in successfully being able to show brain decompression illness on imaging. The imaging results were so dramatic after hyperbaric oxygen therapy that the radiologists didn’t even know how to read it! This is about the time when Dr. Harch’s road to patient care took a straight-shot towards healing a larger variety of indications with HBOT.
His goal today is the same as it was back then…. prove to everyone that Hyperbaric Oxygen Therapy WORKS! Dr. Harch has no plans to retire and stresses that he wants to see this all over the finish line.
Dr. Harch has used HBOT to change the lives of children and adults; but it was his own life that was also greatly changed by the power of hyperbarics. Hyperbaric Oxygen Therapy has allowed Dr. Harch to take the elements of oxygen and pressure, & implement them into healing protocols that have now saved countless lives.
Subscribe Now, It’s Free !
Guest
Dr. Paul G. Harch, MD
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Recent HBOT News
Senate VA Committee Passes Legislation on Hyperbaric Oxygen Therapy
Back in October 2019, at Senator Cramer’s invitation, VA Secretary Robert Wilkie and the Senator toured Healing with Hyperbarics of North Dakota, a Fargo-based HBOT clinic. Cramer states, “The primary point of the federal government is the defense of our nation. Part...
Clinical Trial – the Use of Magnesium Sulfate for Prevention of Postspinal Shivering
Shivering is an unpleasant experience after spinal anesthesia. Shivering is defined as an
involuntary, repetitive activity of skeletal muscles. The mechanisms of shivering in patients
undergoing surgery are mainly intraoperative heat loss, increased sympathetic tone, pain, and
systemic release of pyrogens. Spinal anesthesia significantly impairs the thermoregulation
system by inhibiting tonic vasoconstriction, which plays a significant role in temperature
regulation. Spinal anesthesia also causes redistribution of core heat from the trunk (below
the block level) to the peripheral tissues. These two effects predispose patients to
hypothermia and shivering. The median incidence of shivering related to regional anesthesia
observed in a review of 21 studies is 55%. Shivering increases oxygen consumption, lactic
acidosis, carbon dioxide production, and metabolic rate by up to 400%. Therefore, shivering
may cause problems in patients with low cardiac and pulmonary reserves. The best way to avoid
these intraoperative and postoperative shivering-induced increases in hemodynamic and
metabolic demands is to prevent shivering in the first place. Although magnesium is among
several pharmacological agents used for the treatment of shivering, its effects on prevention
of shivering during central neuraxial blockade have not been evaluated to date. Henceforth,
the aim of this study was to evaluate the effect of magnesiume on shivering during spinal
anesthesia.
Aim:
to compare the efficacy of intravenous versus intrathecal magnesium sulphate for prevention
of post spinal shivering in adult patients undergoing elective lower limb orthopedic
surgeries.
Clinical Trial – Comparing the Effects of Levobupivacaine and Bupivacaine in Saddle Spinal Anesthesia
İn this study; it was aimed to investigate the effects of equipotent doses of hyperbaric
bupivacaine and hyperbaric levobupivacaine in outpatient anorectal surgery under saddle
block. Sixty patients between the age of 18- 50 and in the risk group of ASA I-II included in
the study. 7,5 mg of 0,5% hyperbaric bupivacaine or 7,5 mg of 0,5% hyperbaric levobupivacaine
injected into the intrathecal space in sitting position through L4-L5 or L5-S1 intervertebral
space in 30 seconds. All patients kept in sitting position for 5 minutes with aid after
intrathecal injection and than layed in supine position, finally they positioned in prone
jack-knife. Hemodynamic parameters like NIBP, HR, SpO2, sensory and motor block
characteristics, duration of analgesia, time of first voiding, mobilization time, patient and
surgeon satisfaction, adverse effects and discharge time were recorded during and after
surgery.